Pulmonary Hypertension - Pipeline Insight, 2024

This “Pulmonary Hypertension- Pipeline Insight, 2024,”report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Pulmonary Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pulmonary Hypertension Understanding

Pulmonary Hypertension: Overview

Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. The symptoms of pulmonary hypertension develop slowly and symptoms get worse as the disease progresses symptoms include shortness of breath, at first while exercising and eventually while at rest, blue or gray skin color due to low oxygen levels depending on skin color, these changes may be harder or easier to see chest pressure or pain, dizziness or fainting spells fast pulse or pounding heartbeat, fatigue, swelling in the ankles, legs and belly area. Pulmonary hypertension is usually diagnosed in people ages 30 to 60.

The risk factors associated with pulmonary hypertension are a family history of the condition, being overweight, smoking, blood-clotting disorders or a family history of blood clots in the lungs, exposure to asbestos and a heart problem by birth with, called a congenital heart defect. There are many other complications that are also related with this disease which are right-sided heart enlargement and heart failure, increase the risk of blood clots in the small arteries in the lungs, irregular heartbeats bleeding in the lungs and other pregnancy complications.

The tests that are commonly performed to diagnose PAH and rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the “6-minute walk test”, which measures how far an individual can walk in that time period and right heart catheterization if an echocardiogram shows pulmonary hypertension, this test may be done to confirm the diagnosis.

Treatment for PAH includes prostaglandins, endothelin receptor antagonists, phosphodiesterase Type 5 inhibitors. Other treatments such as anticoagulants, diuretics, and oxygen may be used to treat PAH as supportive therapies. Medicines to relax blood vessels also called vasodilators, these medicines help open narrowed blood vessels and improve blood flow like epoprostenol (Flolan, Veletr), treprostinil and soluble guanylate cyclase (sGC) stimulators high-dose calcium channel blockers by adopting these treatment plans the disease can be controlled and treated to the minimal levels.

Pulmonary Hypertension- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Hypertension pipeline landscape is provided which includes the disease overview and Pulmonary Hypertension treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Hypertension.

Pulmonary Hypertension Emerging Drugs Chapters

This segment of the Pulmonary Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary Hypertension Emerging Drugs

Sotatercept: Merck & Co. Inc.Sotatercept is a potential first-in-class activin signaling inhibitor biologic it is an investigational soluble activin receptor type IIA fusion protein that binds to activins and growth differentiation factors. Sotatercept was acquired as part of the acquisition of Acceleron by Merck & Co. The drug has been granted Breakthrough Therapy Designation and Orphan Drug designation by the U.S. Food and Drug Administration (FDA), as well as Priority Medicines designation and Orphan Drug designation by the European Medicines Agency. In September 2023, Merck announced that the US Food and Drug Administration (FDA) had accepted for priority review a new Biologics License Application (BLA) for sotatercept, Merck’s novel investigational activin signaling inhibitor, for the treatment of adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1). The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of March 26, 2024.

Rodatristat ethyl : Altavant Sciences GmbHRodatristat ethyl is a tryptophan hydroxylase (TPH) Inhibitor designed to reduce the body's peripheral production of serotonin by lowering circulating serotonin levels, rodatristat ethyl may halt or reverse the pathology of diseases that are driven by excessive serotonin production, such as PAH. The drug candidate is currently being evaluated in the Phase II studies for the treatment of Pulmonary Hypertension.

PDNO : Atgeno ABPDNO is the first and only intravenous drug. Supernitro drug candidate uses of nitric oxide. The drug is developed to selectively widen the blood vessels in the lungs. The patient receives Supernitro as an intravenous infusion nitric oxide is delivered in the natural way via the blood-vessels to the heart and lungs. The pressure in the lung circulation is lowered by widening all the targeted local blood vessels in the lungs. Currently the drug is being evaluated in Phase II for the treatment of Pulmonary Hypertension.

BAY 1237592 : BayerBAY 1237592 is a small molecule drug that targets sGC(Soluble guanylate cyclase) and works on sGC stimulants(Soluble guanylate cyclase stimulants) mechanism of action. Currently the drug is being evaluated in Phase I for the treatment of Pulmonary Hypertension.

Pulmonary Hypertension: Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary Hypertension drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pulmonary Hypertension

There are approx. 45+ key companies which are developing the therapies for Pulmonary Hypertension. The companies which have their Pulmonary Hypertension drug candidates in the most advanced stage, i.e., Registered include, Merck & Co. Inc.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pulmonary Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Hypertension: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pulmonary Hypertension therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Hypertension drugs.

Pulmonary Hypertension Report Insights

• Pulmonary Hypertension Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pulmonary Hypertension Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pulmonary Hypertension drugs?
• How many Pulmonary Hypertension drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Hypertension?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Hypertension therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pulmonary Hypertension and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck & Co. Inc
• Altavant Sciences GmbH
• Attgeno AB
• Bayer
• Tenax Therapeutics, Inc
• AstraZeneca
• OrphAI Therapeutics
• Actelion
• Merck & Co. Inc
• Geliad Sciences
• United Therapeutics
• Novartis Pharmaceuticals

Key Products

• Sotatercept
• Rodatristat ethyl
• PDNO
• BAY 1237592
• TNX-103
• AZD3427
• LAM-001
• Selexipag
• MK-5475
• Ambrisentan
• Inhaled Treprostinil
• LTP001

This product will be delivered within 1-3 business days.